Early, Consistent Glucose Control May Be Key to CVD Risk Reduction in Type 2 Diabetes: A Primary Care Analysis
In adults with type 2 diabetes seen in primary care, lowering glucose substantially during the first 12 months post-diagnosis decreased risk for future MACE.
Tezepelumab Reduces Asthma Exacerbations by More than Half, Reports NAVIGATOR Study Author
Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 18, 2022
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Real-world Data Showed Mepolizumab Reduced Exacerbations, Oral Corticosteroid Use in Adults with Severe Asthma
ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.
SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.
Majority of Asthma Patients Prescribed Dupilumab vs Other Biologics as Initial Rx, According to Extensive Real-world Analysis
ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 17, 2022
FDA Authorizes Pfizer-BioNTech COVID-19 Booster for Children Aged 5 to 11 Years
Children aged 5 to 11 years can receive a single dose booster shot 5 months after completing a primary 2-dose series of the Pfizer COVID-19 vaccine, FDA says.
Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim
ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.
NAVIGATOR Data Presented at ATS 2022 Show Improved Clinical Responses to Treatment with Tezepelumab vs Placebo
ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 16, 2022
Novel Fixed-dose Albuterol-Budesonide Inhaler Significantly Reduced Exacerbation Risk in Severe Asthma
ATS 2022: A fixed dose SABA/corticosteroid combination reduced risk of exacerbation by 27% vs SABA alone in the MANDALA study.
First-in-Class Tirzepatide Wins FDA Approval for Treatment of Type 2 Diabetes
Tirzepatide, a novel once-weekly GLP-1/GIP mimetic that binds to receptors and stimulates glucose-dependent insulin release, has shown superiority over many common antihyperglycemics.
Objective Confirmation of Asthma Diagnosis Often Missing in Primary Care, Study Suggests
ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.
Quality of HTN-related Videos on TikTok: Study Author Shares Findings
Lead author of a recent study sat down with Patient Care to discuss how clinicians are using the popular video sharing app and the quality of content available.
Multiancestry Genetic Study of T2D Expands Potential for Risk Assessment, Treatment
A study of the most genetically diverse collection of DNA from persons with T2D yields 40 new potentially causative genes that may transcend ancestry.
Half of Hospitalized COVID-19 Survivors Report at Least 1 Enduring Symptom at 2 Years
Long COVID symptoms affected 55% of persons hospitalized for the infection, regardless of severity of initial illness, report a Chinese team of investigators.
National Survey Finds Primary Care in Crisis
Primary care clinician burnout is at an all-time high and 25% of clinicians plan to leave within the next 3 years, according to a recent US survey.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 12, 2022
Patient-centered Treatment for Obesity: Guidelines from the Canadian Obesity Society
The Canadian Obesity Society advocates for a therapeutic approach to obesity that removes stigma, focuses on individual patient goals, and favors body health over body weight.
